April 27, 2017 (Investorideas.com Newswire) Maxim Group noted that data from Zynerba’s Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials.
Zynerba Pharmaceuticals Inc. (ZYNE:NASDAQ) expects to release data in the third quarter from its Phase 2 STAR (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) trial for ZYN002 in adult refractory focal seizures. In the trial, according to Maxim’s March 28 report, the patients “have been randomized to receive 195mg, 390mg, or placebo. The primary end point is median percentage change in seizure frequency over the 12-week treatment period.”
“Of 110 patients who have completed the STAR 1 study, 106 patients have enrolled into STAR 2, an open label long-term safety and tolerability study of ZYN002 for up to 52 weeks. After completion of Phase II, the company expects to meet with the
... read more at: http://www.investorideas.com/news/2017/biotech/04273Zynerba.asp